Supriya Lifescience Limited: history, ownership, mission, how it works & makes money

A Brief History of Supriya Lifescience Limited

Founded in 2007, Supriya Lifescience Limited operates in the pharmaceutical sector, primarily focusing on the production of Active Pharmaceutical Ingredients (APIs) and intermediates. Based in Maharashtra, India, the company has established itself as a key player in supplying various APIs to global markets.

In fiscal year 2021-22, Supriya Lifescience recorded a revenue of **₹6,200 million** (approx. **$82 million**), showcasing a growth trajectory that reflects its expanding operational capacity and market reach. The company's net profit for the same period was **₹1,060 million** (approx. **$14 million**), indicating a healthy profit margin of approximately **17%**.

Supriya Lifescience’s product portfolio includes over **30 APIs**, catering to therapeutic areas such as anti-histamines, anti-diabetics, anti-inflammatory, and cardiovascular drugs. The company has a strong presence in global markets, exporting to over **100 countries**, including the United States, Europe, and other emerging markets.

In terms of its manufacturing capabilities, Supriya Lifescience boasts two state-of-the-art manufacturing facilities certified by the US FDA, WHO, and other regulatory bodies. These facilities are equipped with advanced technology to maintain the highest standards in production and quality control.

As of October 2023, Supriya Lifescience's market capitalization is approximately **₹28 billion** (around **$370 million**), reflecting strong investor confidence and an upward trend in stock performance. The stock price has seen a year-to-date increase of approximately **30%**, demonstrating resilience amid market fluctuations.

The company has also announced an investment of approximately **₹1 billion** ($13 million) aimed at expanding its production capacity and enhancing R&D efforts to develop new APIs and formulations as part of its strategic growth plan for 2023-2025.

Furthermore, Supriya Lifescience's commitment to sustainability and ethical practices is evident in its efforts to minimize environmental impact and adhere to global standards in supply chain management.

A Who Owns Supriya Lifescience Limited

Supriya Lifescience Limited, a prominent player in the pharmaceutical sector, is significantly owned by various stakeholders including institutional investors, mutual funds, and individual shareholders. The ownership structure can provide insight into the company's stability and investor confidence.

The data reflects the ownership structure as of the last reported quarter in September 2023. Notably, the promoters hold a significant majority with 74.54% of the shares, indicating strong control and influence over company decisions.

As of September 2023, Supriya Lifescience Limited's market capitalization stood at approximately ₹4,000 crores. The company's stock performance has shown resilience, trading around ₹550 per share, following a steady increase attributed to growth in the pharmaceutical sector.

In terms of recent financial performance, Supriya Lifescience reported a revenue of ₹400 crores for the quarter ending June 2023, marking a year-over-year growth of 20%. This growth is driven by both domestic and international demand for its active pharmaceutical ingredients (APIs).

The revenue breakdown indicates that around 60% of sales come from exports, highlighting the company's global reach and dependence on international markets. The remaining 40% is generated from domestic sales within India.

Another important statistic is the company’s strong EBITDA margin, which as of the last financial report, was recorded at 25%. This reflects effective cost management and pricing power in the competitive pharmaceutical landscape.

Investors and analysts closely watch the shareholder dynamics as the presence of institutional investors can often signal confidence in the company's future. However, in this case, institutional ownership appears minimal, which may raise questions for some investors.

Overall, the ownership structure of Supriya Lifescience Limited showcases a strong promoter presence, indicating a focused strategy for growth and stability in the evolving pharmaceutical sector.

Supriya Lifescience Limited Mission Statement

Supriya Lifescience Limited, a prominent player in the pharmaceutical and life sciences arena, articulates its mission statement to reflect its commitment to quality, innovation, and accessibility. The mission emphasizes delivering high-value pharmaceutical products globally while adhering to stringent regulatory standards.

The company aims to focus on advancing healthcare solutions through research and development, with a special emphasis on active pharmaceutical ingredients (APIs) and intermediates. This strategy is designed to ensure that their products meet the evolving needs of customers and regulatory bodies.

As per their mission, Supriya Lifescience is dedicated to maintaining robust ethical standards, ensuring sustainability in operations, and contributing to the well-being of communities where they operate. This holistic approach not only enhances their brand reputation but also drives business performance.

Supriya Lifescience has reported substantial growth in its operations, with a focus on strategic alliances and collaborations that enhance their market position. The integration of advanced technologies in their production processes has enabled them to innovate while adhering to high standards.

Additionally, their commitment to Corporate Social Responsibility (CSR) initiatives aligns with their mission statement, focusing on community health and education programs. This not only establishes a positive public image but also fosters loyalty among stakeholders.

In summary, Supriya Lifescience Limited continues to steer its efforts toward fulfilling its mission, demonstrating resilience in a competitive landscape while ensuring that their products and services remain at the forefront of the pharmaceutical industry.

How Supriya Lifescience Limited Works

Supriya Lifescience Limited, primarily engaged in the manufacturing of active pharmaceutical ingredients (APIs), operates in various segments including healthcare, nutrition, and pharmaceuticals. The company specializes in producing a wide range of APIs catering to therapeutic areas such as analgesics, antibiotics, and anti-allergics.

As of the latest financial statements, Supriya Lifescience reported a revenue of INR 294.79 crore for the fiscal year 2023, showing a substantial growth when compared to INR 232.73 crore in 2022. This reflects a year-over-year increase of approximately 26.67%.

The company's operations are primarily divided into API production, which constitutes a significant portion of their revenue, and contract research services. Supriya Lifescience maintains a robust R&D program, with approximately 6% of its revenue allocated to research and development activities. This investment has led to the successful launch of new products and enhanced production capabilities.

In terms of geographical presence, Supriya Lifescience exports to over 85 countries, contributing to approximately 40% of the total revenue. Major markets include the United States, Europe, and Asia-Pacific regions.

During FY 2023, the company achieved an export revenue of about INR 117.91 crore, which is an increase from INR 92.48 crore in FY 2022. This trend indicates the company’s growing footprint in international markets.

Supriya Lifescience is equipped with modern manufacturing facilities that comply with Good Manufacturing Practices (GMP) and various international regulatory standards. The facilities are capable of producing a diverse range of APIs, with a production capacity of over 50 metric tons per month.

In its product lineup, the company has also focused on expanding its portfolio in specialty chemicals, which further enhances its revenue diversity. The contribution from specialty chemicals has grown to around 30% of total sales.

As of October 2023, Supriya Lifescience's market capitalization stands at approximately INR 1,550 crore with a share price of around INR 445. The stock has shown a significant performance, with a return of about 40% year-to-date, reflecting investor confidence in the company’s growth strategy and execution.

How Supriya Lifescience Limited Makes Money

Supriya Lifescience Limited, a prominent player in the pharmaceuticals and chemical industry, generates revenue through a diversified portfolio of products and services. The company's operations are primarily segmented into APIs (Active Pharmaceutical Ingredients) and formulations.

Revenue Sources

• APIs: Supriya Lifescience is focused on manufacturing APIs, supplying to various international markets. In FY 2022-23, the company reported revenue from API sales of INR 270 crores, contributing to a significant portion of total revenue.
• Formulations: The formulation segment includes finished dosage forms. The revenue from this segment in FY 2022-23 was approximately INR 180 crores.
• Export Markets: The company exports its products to over 100 countries, including regulated markets like the USA and Europe, which represented around 70% of its total revenue.
• Chemical Products: Additional revenue stems from specialty chemicals, which added about INR 60 crores to the overall financial performance.

Financial Performance Metrics

In the latest financial year, Supriya Lifescience Limited reported the following key financial figures:

Market Positioning and Strategy

Supriya Lifescience aims to enhance its market positioning by focusing on research and development. In FY 2022-23, the company invested around INR 20 crores in R&D initiatives to innovate its product range and improve production capabilities.

Growth Prospects

The company has outlined ambitious plans for expansion, targeting a revenue CAGR of 15% over the next five years. Investment in state-of-the-art manufacturing facilities is also underway, with an estimated cost of INR 150 crores planned for the upcoming fiscal year.

Key Partnerships and Collaborations

• Supriya Lifescience has established key partnerships with multinational companies, resulting in collaborative projects that enhance production efficiency and market reach.
• Joint ventures with international entities have facilitated entry into new markets, increasing export capabilities.

Conclusion on Financial Outlook

As of the second quarter of FY 2023-24, the company's stock has shown resilience, with shares trading at around INR 350, reflecting a 15% increase year-to-date. Analysts anticipate steady growth, driven by global demand for pharmaceuticals and strategic initiatives to expand product offerings.